Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents

Circulation

Volumn 113, Issue 8, 2006, Pages 1108-1113

  Kuchulakanti, Pramod K ^a   Chu, William W ^a   Torguson, Rebecca ^a   Ohlmann, Patrick ^a   Rha, Seung Woon ^a   Clavijo, Leonardo C ^a   Kim, Sang Wook ^a   Bui, Ahn ^a   Gevorkian, Natalie ^a   Xue, Zhenyi ^a   Smith, Kimberly ^a   Fournadjieva, Jana ^a   Suddath, William O ^a   Satler, Lowell F ^a   Pichard, Augusto D ^a   Kent, Kenneth M ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Angioplasty; Clopidogrel; Stents; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PACLITAXEL; RAPAMYCIN; TICLOPIDINE; DRUG DERIVATIVE;

ADULT; AGED; ANGIOGRAPHY; AORTA BALLOON; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; HUMAN; IN-STENT RESTENOSIS; KIDNEY FAILURE; MALE; MORTALITY; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STENT THROMBOSIS; THROMBOSIS; CASE CONTROL STUDY; DRUG DELIVERY SYSTEM; FOLLOW UP; GRAFT OCCLUSION; MIDDLE AGED; STENT; TREATMENT OUTCOME;

AGED; ANGIOGRAPHY; CASE-CONTROL STUDIES; DRUG DELIVERY SYSTEMS; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; PACLITAXEL; SIROLIMUS; STENTS; THROMBOSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 33645311266     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.600155     Document Type: Article

References (17)

1. Kereiakes DN, Choo JK, Young JJ, Broderick TM. Thrombosis and dmg-eluting stents: a critical appraisal. Rev Cardiovasc Med. 2004;5:9-15.
2. van der Hoeven BL, Pires NM, Warda HM, Oemrawsingh PV, van Vlijmen BJ, Quax PH, Schalij MJ, van der Wall EE, Jukema JW. Drug-eluting stents: results, promises and problems. Int J Cardiol. 2005;99:9-17.
3. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol. 2004;44:1373-1385.
4. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, Corrozza JP, Chauhan MS, Rodrigues O, Kuntz RE. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001;103:1967-1971.
5. Moussa I, Di Mario C, Reimers B, Akiyama T, Tobis J, Colombo A. subacute stent thrombosis in the era of intravascular ultrasound guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol. 1997;29:6-12.
6. Schuhlen H, Kastrati A, Dirschinger J, Hausleiter J, Elezi S, Wehinger A, Pache J, Hadamitzky M, Schomig A. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation. 1998;98:104-111.
7. Silva JA, Ramee SR, White CJ, Collins TJ, Jenkins JS, Nunez E, Zhang S, Jain SP. Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome. Am Heart J. 1999;138:446-455.
8. Honda Y, Fitzgerald PJ. Stent thrombosis: an issue revisited in a changing world. Circulation. 2003;108:2-5.
9. Wang F, Stouffer GA, Waxman S, Uretsky BF. Late coronary stent thrombosis: early vs. late stent thrombosis in the stent era. Catheter Cardiovasc Interv. 2002;55:142-147.
10. Waksman R, Ajani AE, White RL, Pinnow E, Dieble R, Bui AB, Taaffe M, Gruberg L, Mintz GS, Satler LF, Pichard AD, Kent KK, Lindsay J. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial Plus 6 Months of Clopidogrel (WRIST PLUS). Circulation. 2001;103:2332-2335.
11. Bavry AA, Kumbhani DJ, Helton T, Bhatt DL. What is the risk of stent thrombosis associated with the use of paclitaxel eluting stents for percutaneous coronary intervention? J Am Coll Cardiol. 2005;45:941-946.
12. Moreno R, Fernandez C, Hernandez R, Alfonso F, Angiolillo DJ, Sabate M, Escaned J, Banuelos C, Fernandez-Ortiz A, Macaya C. Drug eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005;45:954-959.
13. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-2130.
14. Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Sonnenschein K, Regar E, McFadden EP, Sianos G, van der Giessen WJ, de Jaegere PP, de Feyter P, van Domburg RT, Serruys PW. Thirty day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol. 2005;45:947-953.
15. Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, Pinto DS, Ho KK, Cohen DJ, Garcia LA, Cutlip DE, Carrozza JP Jr. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation. 2004;109:1930-1932.
16. Ong ATL, Mc Fadden EP, Regar E, Jaegere PT, Dombrg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005;45:2088-2092.
17. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701-705.